Aria Soars 26% on Promising Drug Results

Ariad Pharmaceuticals

(ARIA)

said studies on its orally active drug candidate for cancer, currently known as AP23573, showed the treatment has the ability to shrink tumors. The study involved animal subjects, not humans. The stock was gaining 26% to $6.09.